Molecular and immunophenotypic characterization of SMARCB1 (INI1) - deficient intrathoracic Neoplasms.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
12 2022
Historique:
received: 01 04 2022
accepted: 20 06 2022
revised: 20 06 2022
pubmed: 22 7 2022
medline: 2 12 2022
entrez: 21 7 2022
Statut: ppublish

Résumé

The switch/sucrose-non-fermenting (SWI/SNF) complex is an ATP-dependent chromatin remodeling complex that plays important roles in DNA repair, transcription and cell differentiation. This complex consists of multiple subunits and is of particular interest in thoracic malignancies due to frequent subunit alteration of SMARCA4 (BRG1). Much less is known about SMARCB1 (INI1) deficient intrathoracic neoplasms, which are rare, often misclassified and understudied. In a retrospective analysis of 1479 intrathoracic malignant neoplasms using immunohistochemistry for INI1 (SMARCB1) on tissue micro arrays (TMA) and a search through our hospital sarcoma database, we identified in total nine intrathoracic, INI1 deficient cases (n = 9). We characterized these cases further by additional immunohistochemistry, broad targeted genomic analysis, methylation profiling and correlated them with clinical and radiological data. This showed that genomic SMARCB1 together with tumor suppressor alterations drive tumorigenesis in some of these cases, rather than epigenetic changes such as DNA methylation. A proper diagnostic classification, however, remains challenging. Intrathoracic tumors with loss or alteration of SMARCB1 (INI1) are highly aggressive and remain often underdiagnosed due to their rarity, which leads to false diagnostic interpretations. A better understanding of these tumors and proper diagnosis is important for better patient care as clinical trials and more targeted therapeutic options are emerging.

Identifiants

pubmed: 35864317
doi: 10.1038/s41379-022-01133-4
pii: S0893-3952(22)05498-9
pmc: PMC9708576
doi:

Substances chimiques

Biomarkers, Tumor 0
SMARCB1 Protein 0
SMARCA4 protein, human EC 3.6.1.-
DNA Helicases EC 3.6.4.-
Nuclear Proteins 0
Transcription Factors 0
SMARCB1 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1860-1869

Informations de copyright

© 2022. The Author(s).

Références

Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
J Pathol Clin Res. 2021 Jul;7(4):350-360
pubmed: 33949149
J Pathol. 2016 Feb;238(3):389-400
pubmed: 26356327
Transl Lung Cancer Res. 2019 Oct;8(5):700-705
pubmed: 31737506
Pan Afr Med J. 2016 Jul 14;24:238
pubmed: 27800093
Nat Commun. 2017 Jan 19;8:14098
pubmed: 28102363
Oncogene. 2009 Apr 9;28(14):1653-68
pubmed: 19234488
J Clin Imaging Sci. 2019 Mar 28;9:7
pubmed: 31448158
Am J Surg Pathol. 2011 Oct;35(10):e47-63
pubmed: 21934399
Mod Pathol. 2014 Jun;27(6):832-9
pubmed: 24287458
Surg Case Rep. 2018 Jul 13;4(1):77
pubmed: 30006912
Clin Cancer Res. 2020 Feb 15;26(4):892-901
pubmed: 31694833
Adv Anat Pathol. 2007 Sep;14(5):335-9
pubmed: 17717433
J Thorac Oncol. 2020 Feb;15(2):231-247
pubmed: 31751681
J Pathol. 2016 Jan;238(1):63-73
pubmed: 26365879
Cancer Res. 2014 Nov 15;74(22):6486-6498
pubmed: 25115300
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
Clin Cancer Res. 2020 Jun 15;26(12):2882-2890
pubmed: 32122923
J Hematol Oncol. 2020 Apr 7;13(1):33
pubmed: 32264965
Mod Pathol. 2013 Mar;26(3):393-403
pubmed: 23174932
Lancet Oncol. 2020 Nov;21(11):1423-1432
pubmed: 33035459
Arch Pathol Lab Med. 2021 Jan 1;145(1):90-98
pubmed: 33367658
Thorac Cancer. 2019 Apr;10(4):839-847
pubmed: 30793508
Nat Commun. 2021 Jan 21;12(1):498
pubmed: 33479225
Mod Pathol. 2017 Apr;30(4):539-548
pubmed: 28084340
Nat Genet. 2015 Oct;47(10):1200-5
pubmed: 26343384
Front Oncol. 2022 Jan 14;11:664397
pubmed: 35096557
Diagn Pathol. 2022 Feb 10;17(1):26
pubmed: 35144629
Ann Diagn Pathol. 2017 Feb;26:47-51
pubmed: 28038711
Cancer Genet. 2014 Sep;207(9):373-8
pubmed: 24933152
Cancer Cell. 2019 Dec 9;36(6):597-612.e8
pubmed: 31708437
Neuro Oncol. 2020 Jun 9;22(6):785-796
pubmed: 31912158
Virchows Arch. 2007 Sep;451(3):669-80
pubmed: 17609977
NAR Cancer. 2022 Mar 03;4(1):zcac007
pubmed: 35252869
Nature. 2015 Apr 9;520(7546):239-42
pubmed: 25629630
Mod Pathol. 2017 Jun;30(6):797-809
pubmed: 28256572
Adv Anat Pathol. 2014 Nov;21(6):394-410
pubmed: 25299309
Nat Commun. 2019 Feb 4;10(1):557
pubmed: 30718506
Nat Genet. 2013 Jun;45(6):592-601
pubmed: 23644491

Auteurs

Martina Haberecker (M)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Marco Matteo Bühler (MM)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Alicia Pliego Mendieta (AP)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Roman Guggenberger (R)

Department of Radiology, University Hospital Zurich, Zurich, Switzerland.

Fabian Arnold (F)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Eva Markert (E)

Institute of Pathology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

Markus Rechsteiner (M)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Martin Zoche (M)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Christian Britschgi (C)

Department of Medical Oncology and Hematology, University Hospital Zurich, Comprehensive Cancer Center Zurich, Zurich, Switzerland.

Chantal Pauli (C)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland. chantal.pauli@usz.ch.
University Zurich, Zurich, Switzerland. chantal.pauli@usz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH